Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + obinutuzumab in treatment-naive follicular lymphoma
ChiCTR2500096190Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib and obinutuzumab in follicular lymphoma (FL), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Complete response rate. Started Jan 2025; status: recruiting.
02
Drugs
zanubrutinibobinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ChiCTR2500096190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096190.